A Phase 1 Study of the TRK Inhibitor Selitrectinib (BAY 2731954) in Adult and Pediatric Subjects With Previously Treated NTRK Fusion Cancers
Latest Information Update: 01 Nov 2024
At a glance
- Drugs Selitrectinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Bayer; Loxo Oncology
- 07 Mar 2023 Status changed from active, no longer recruiting to completed.
- 30 Jan 2023 This trial has been completed in Belgium , according to European Clinical Trials Database record.
- 30 Jan 2023 Planned End Date changed from 31 Dec 2022 to 30 Jan 2023.